Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703313 · ClinicalTrials.gov registry record · Phase 4
Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators
A Phase 4 study, sponsored by Santen.
- Completed
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
NCT00703313: Completed Phase 4 study, sponsored by Santen.
NCT00703313 is a Phase 4 study that has completed, run by Santen. The registered enrollment target is 72 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00703313, a Phase 4 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the concentration in human tears of levofloxacin and the active comparators at 15 minutes, 2,6, 12, and 24 hours after instillation of a single drop of medication.
Interventions
- DRUG 1.5% levofloxacin ophthalmic solution
- DRUG 0.5% moxifloxacin hydrochloride ophthalmic solution
- DRUG 0.3% gatifloxacin ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2008-05 |
| Phase | Phase 4 |
What the finished NCT00703313 record still lists
NCT00703313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 3 interventions - of which 1.5% levofloxacin ophthalmic solution is the first listed.
NCT00703313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00703313 about?
NCT00703313 is a clinical study titled "Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators". The primary objective of this study is to compare the concentration in human tears of levofloxacin and the active comparators at 15 minutes, 2,6, 12, and 24 hours after instillation of a single drop of medication.
What is the current status of trial NCT00703313?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2008-05.
What interventions are being tested in trial NCT00703313?
The interventions under investigation include: 1.5% levofloxacin ophthalmic solution (DRUG), 0.5% moxifloxacin hydrochloride ophthalmic solution (DRUG), 0.3% gatifloxacin ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00703313?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00703313's enrollment target sits among peer trials
72 1035th of 2000 higher than 961 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia